<SEC-DOCUMENT>0001193125-25-329186.txt : 20251223
<SEC-HEADER>0001193125-25-329186.hdr.sgml : 20251223
<ACCEPTANCE-DATETIME>20251222201151
ACCESSION NUMBER:		0001193125-25-329186
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20251222
FILED AS OF DATE:		20251223
DATE AS OF CHANGE:		20251222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		251593944

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d93446d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;6-K </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE&nbsp;13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as December 22, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number&nbsp;001-35428 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#8217;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level&nbsp;32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form 40-F&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T
Rule&nbsp;101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by
Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If &#8220;Yes&#8221; is marked, indicated below the file number assigned to the registrant in connection with Rule&nbsp;12g3-2(b): Not
applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><A HREF="d93446dex991.htm">Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases,
 from Phase I Study </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: December 22, 2025 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d93446dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g93446g1222222808082.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Immutep Announces Positive Update on IMP761, a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Class</FONT></FONT> <FONT STYLE="white-space:nowrap">LAG-3</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Agonist Antibody for Autoimmune Diseases, from Phase I Study </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levels</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Dose dependent immunosuppressive effect </I><I>against a strong foreign antigen </I><I>observed with continued
favourable safety profile</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Substantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseases</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Given encouraging efficacy and safety, the trial will continue as planned and further updates are anticipated in 1H
CY2026 including presentation of data at a major medical conference</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>SYDNEY, AUSTRALIA &#8211;
December</B><B></B><B>&nbsp;22, 2025 &#8211;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep&#8221; or &#8220;the Company&#8221;), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces a
positive update from the placebo-controlled, double-blind <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase I study in healthy participants evaluating IMP761, a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody for autoimmune diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The
single-ascending dose escalation portion of the trial has successfully completed the 2.5 and 7 mg / kg dosing levels of IMP761 with continued positive safety and efficacy data. IMP761 was tolerated well with no treatment-related adverse reactions
beyond mild intensity. Additionally, evidence of dose dependent immunosuppressive effects with IMP761 was observed with significant, long-lasting inhibition of the three <FONT STYLE="white-space:nowrap">T-cell-mediated</FONT> intradermal reactions
to a strong foreign antigen at day 2, 9 and 23. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>Dr.</B><B></B><B>&nbsp;Fr&eacute;d&eacute;ric Triebel, CSO of Immutep, said</B>: &#8220;We are
excited to see IMP761 having a long-term immunosuppressive effect after a single injection. A solid pharmacokinetic/pharmacodynamic relationship has now been established between 1 and 7 mg/kg with eight participants per group to cover the
variability of the responses. This novel immunotherapy&#8217;s significant level of immune suppression combined with its favourable safety provide <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data
in its potential to silence the dysregulated T cells at the epicenter of many autoimmune diseases. Encouragingly, our clinical progress with IMP761 has corresponded with increased external interest in this program.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The <FONT STYLE="white-space:nowrap">LAG-3</FONT> (lymphocyte-activation <FONT STYLE="white-space:nowrap">gene-3)</FONT> immune checkpoint has been
identified as a promising therapeutic target for many autoimmune diseases, including rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis.<SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="white-space:nowrap">1-3</FONT></SUP>
IMP761 is the first <FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody developed to potentially treat these large, increasingly prevalent disorders, each of which represent multi-billion dollar markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">By enhancing the &#8220;brake&#8221; function of <FONT STYLE="white-space:nowrap">LAG-3</FONT> to silence dysregulated self-antigen-specific memory T
cells, IMP761 is designed to target the cause of autoimmune diseases and restore balance to the immune system. <FONT STYLE="white-space:nowrap">LAG-3</FONT> expression on activated T cells demonstrates high specificity for disease sites, especially
in regions characterised by chronic inflammation. This distinct characteristic of the <FONT STYLE="white-space:nowrap">LAG-3</FONT> immune checkpoint suggests IMP761 may enable a more targeted therapeutic approach with fewer adverse effects compared
to other treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Given the encouraging efficacy and safety to date, the trial will continue as planned and additional updates are anticipated
in the first half of CY2026 including a potential presentation of data at a major medical conference in the field of autoimmune diseases. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:8pt"><B>Immutep Limited</B>, Level 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia; ABN: 90 009 237 889</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g93446g1222222808249.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About IMP761 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">IMP761, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> immunosuppressive lymphocyte-activation <FONT
STYLE="white-space:nowrap">gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3)</FONT> agonist antibody, has the potential to address the root cause of many autoimmune diseases by specifically silencing autoimmune memory T cells that accumulate at
disease sites and restoring balance to the immune system. As published in the <U>Journal of Immunology</U>, encouraging <FONT STYLE="white-space:nowrap">pre-clinical</FONT> in vivo and in vitro studies show IMP761 inhibits peptide-induced T cell
proliferation, activation of human primary T cells, and an antigen-specific delayed-type hypersensitivity (DTH) reaction.<SUP STYLE="font-size:75%; vertical-align:top">4</SUP> Additional preclinical data in oligoarticular juvenile idiopathic
arthritis <FONT STYLE="white-space:nowrap">(o-JIA)</FONT> published in <U>Pediatric Research</U> details how IMP761 led to a decrease in a broad spectrum of effector cytokines.<SUP STYLE="font-size:75%; vertical-align:top">5</SUP> This study also
shows children with <FONT STYLE="white-space:nowrap">o-JIA</FONT> have a skewed <FONT STYLE="white-space:nowrap">LAG-3</FONT> metabolism and suggests they can benefit from agonistic <FONT STYLE="white-space:nowrap">LAG-3</FONT> activity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Immutep is a late-stage biotechnology company
developing novel immunotherapies for cancer and autoimmune disease<I>.</I> The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT><B> </B><FONT
STYLE="white-space:nowrap">(LAG-3),</FONT> and its diversified product portfolio harnesses <FONT STYLE="white-space:nowrap">LAG-3&#8217;s</FONT> ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise
to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com.</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><I>Pedersen, J.M., Hansen, A.S., Skej&oslash;, C. et al. Lymphocyte activation gene 3 is increased and affects
cytokine production in rheumatoid arthritis. Arthritis Res Ther 25, 97 (2023). <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://doi.org/10.1186/s13075-023-03073-z</FONT></FONT> </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><I>Jones BE, Maerz MD et al. Fewer <FONT STYLE="white-space:nowrap">LAG-3+</FONT> T Cells in Relapsing-Remitting
Multiple Sclerosis and Type 1 Diabetes. J Immunol. 2022 Feb <FONT STYLE="white-space:nowrap">1;208(3):594-602.</FONT> doi: 10.4049/jimmunol.2100850. Epub 2022 Jan 12. PMID: 35022272; PMCID: PMC8820445. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>3.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><I>Zhou X, Gu Y et al. From bench to bedside: targeting lymphocyte activation gene 3 as a therapeutic strategy for
autoimmune diseases. Inflamm Res. 2023 Jun;72(6):1215-1235. doi: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">10.1007/s00011-023-01742-y.</FONT></FONT></FONT> Epub 2023 Jun 14. PMID: 37314518.
</I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>4.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><I>Mathieu Angin, Chrystelle Brignone, Fr&eacute;d&eacute;ric Triebel; A
<FONT STYLE="white-space:nowrap">LAG-3&#8211;Specific</FONT> Agonist Antibody for the Treatment of T Cell&#8211;Induced Autoimmune Diseases. J Immunol 15&nbsp;February 2020; 204 (4): 810&#8211;818. https://doi.org/10.4049/jimmunol.1900823
</I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>5.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify"><I>Sag, E., Demir, S., Aspari, M. et al. Juvenile idiopathic arthritis: lymphocyte activation <FONT
STYLE="white-space:nowrap">gene-3</FONT> is a central immune receptor in children with oligoarticular subtypes. Pediatr Res 90, 744&#8211;751 (2021).
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://doi.org/10.1038/s41390-021-01588-2</FONT></FONT></FONT> </I></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Eleanor Pearson, Sodali&nbsp;&amp; Co. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">+61 2 9066 4071; <U>eleanor.pearson@sodali.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>U.S. Investors/Media:
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Chris Basta, VP, Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">+1 (631)
318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">This announcement was authorised for release by the CEO of Immutep Limited. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:8pt"><B>Immutep Limited</B>, Level 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia; ABN: 90 009 237 889</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g93446g1222222808249.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g93446g1222222808082.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g93446g1222222808082.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ^ +0# 2(  A$! Q$!_\0
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M3X6T#Q-8^'M1U^PLM<OL?9[":<++)DX7 ]R"!Z]JZ2G9H2:>S"BBBD,****
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MO,9)Y. 1GH!12G&FW#F^8\31J5U"KR:K>-S*D_X)M^$HXV>3QCK"HHR6:*$
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%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g93446g1222222808249.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g93446g1222222808249.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  @ !\# 2(  A$! Q$!_\0
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2)P]*MF==5*L=.KVT[?UJ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
